Ask about Mazdutide

Get a grounded answer across clinical evidence, community patterns, and risks.

Ask AI →

Mazdutide

Also known as: IBI362, LY3305677

Weight Loss Phase 3 Trials

GLP-1/Glucagon dual receptor agonist

Mechanism of Action

An oxyntomodulin-analog glucagon/GLP-1 dual agonist promoting satiety and energy expenditure. In late-stage trials, primarily in China.

245
Community Posts
95
Users Discussing
18
Research Articles
12
Clinical Trials

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=245).

Weight Loss

Reduction in body weight

Clinical: B
Community: B
26% (42)
Sleep Quality

Effects on sleep quality

Clinical: D
Community: B
25% (27)
Appetite Suppression

Reduced hunger and food cravings

Clinical: B
Community: B
16% (22)
Cardiovascular

Effects on heart health markers

Clinical: B
Community: B
10% (13)
Blood Sugar Control

Improved glycemic control and insulin sensitivity

Clinical: A
Community: C
8% (18)
Energy Levels

Changes in energy and fatigue levels

Clinical: C
Community: B
8% (11)
Mental/Mood

Effects on mood and cognitive function

Clinical: D
Community: C
6% (9)
Body Composition

Changes in muscle vs fat ratio

Clinical: D
Community: B
4% (5)

Side Effects

Limited data

Based on 11 user reports (n=11). Frequency indicates how often each was mentioned.

Common (>5%)

Fatigue
Mild 3 reports 27.3%
Constipation
Mild 2 reports 18.2%

Uncommon (1-5%)

Lethargy
Mild 1 reports 9.1%
Tiredness
Mild 1 reports 9.1%
Headaches
Mild 1 reports 9.1%
Anxiety
Mild 1 reports 9.1%
Dehydration
Mild 1 reports 9.1%
Muscle Loss
Mild 1 reports 9.1%
Extreme Sensitivity To Lactose
Mild 1 reports 9.1%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

i

Gastrointestinal Issues

11 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

3 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
1.5-3mg weekly (research/trial protocols)
Titration
Titrate over weeks to target dose
Half-life
Weekly dosing (long-acting)
Administration
Subcutaneous injection, once weekly

Community Dosing Patterns

Based on 15 mentions

Community-reported patterns, not medical advice.

3mg weekly
2
2mg weekly
2
2.5mg
1
1.5mg daily
1
1.5mg weekly
1

Research

18
Total Articles
12
Clinical Trials
9
Reviews

Key Studies

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Clinical Trial

Nat Commun (2023)

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clinical Trial

Diabetes Care (2024)

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Clinical Trial

Diabetes Obes Metab (2025)

Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations Review

Drugs Context (2025)

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. Review

J Obes (2025)

Commonly Stacked With

From community members' documented stacks involving Mazdutide.

Tirzepatide 13 stacks (72.2%)
Retatrutide 4 stacks (22.2%)
Cagrilintide 3 stacks (16.7%)

Switching Patterns

Based on 15 discussions about switching to or from Mazdutide.

→ Switching FROM

Retatrutide 3 mentions

Users who switched to Mazdutide

← Switching TO

Retatrutide 6 mentions

Users who switched from Mazdutide